4//SEC Filing
Vanda Pharmaceuticals Inc. 4
Accession 0001209191-13-053649
$VNDACIK 0001347178operating
Filed
Nov 20, 7:00 PM ET
Accepted
Nov 21, 8:02 PM ET
Size
21.0 KB
Accession
0001209191-13-053649
Insider Transaction Report
Form 4
Repella Robert
SVP & Chief Commercial Officer
Transactions
- Sale
Common Stock
2013-11-20$11.89/sh−40,515$481,659→ 21,490 total - Exercise/Conversion
Common Stock
2013-11-21$5.90/sh+23,040$135,936→ 44,530 total - Sale
Common Stock
2013-11-21$12.12/sh−64,100$776,789→ 15,000 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2013-11-20−40,515→ 189,485 totalExercise: $5.90Exp: 2021-10-24→ Common Stock (40,515 underlying) - Exercise/Conversion
Employee Stock Option (Right to Buy)
2013-11-21−23,040→ 166,445 totalExercise: $5.90Exp: 2021-10-24→ Common Stock (23,040 underlying) - Exercise/Conversion
Employee Stock Option (Right to Buy)
2013-11-21−34,570→ 21,680 totalExercise: $3.12Exp: 2022-12-06→ Common Stock (34,570 underlying) - Sale
Common Stock
2013-11-19$12.07/sh−2,885$34,829→ 21,490 total - Exercise/Conversion
Common Stock
2013-11-21$3.12/sh+34,570$107,858→ 79,100 total - Exercise/Conversion
Common Stock
2013-11-20$5.90/sh+40,515$239,039→ 62,005 total
Footnotes (6)
- [F1]Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of certain Restricted Stock Units.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.03 to $12.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2), (3) and (4) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.80 to $12.115, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.80 to $12.46, inclusive.
- [F5]The option becomes exercisable with respect to 25% of the shares after 12 months of continuous service with the Issuer, with the balance becoming exercisable in equal monthly installments over the next 36 months of continuous service thereafter.
- [F6]50% of the shares subject to this option shall vest in 48 equal monthly installments beginning January 7, 2013 (the "Initial Vesting Date"), provided Reporting Person remains continuously employed by the Issuer through the Initial Vesting Date. 50% of the shares subject to this option shall vest upon acceptance by the U.S. Food and Drug Administration of the Issuer's New Drug Application Filing for tasimelteon for the treatment of Non-24-Hour Disorder (the "Vesting Event"), provided Reporting Person remains continuously employed by the Issuer through the Vesting Event.
Documents
Issuer
Vanda Pharmaceuticals Inc.
CIK 0001347178
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001347178
Filing Metadata
- Form type
- 4
- Filed
- Nov 20, 7:00 PM ET
- Accepted
- Nov 21, 8:02 PM ET
- Size
- 21.0 KB